<p>蒙特利尔，魁北克 --（Newsfile Corp. -2026 年 1 月 21 日）- Defence Therapeutics Inc.（CSE: DTC）（FSE: DTC）（OTCQB: DTCFF）（“Defence” 或 “公司”），一家上市生物技术公司，今天宣布其企业定位的演变，以反映其作为一家精确细胞内药物递送公司的专注，正在通过内部开发项目和战略合作伙伴关系推进其专有的 Accum®平台。Accum®旨在释放复杂癌症生物制剂的全部潜力，增强细胞内递送以提高治疗效力，同时降低毒性。</p>
<p>这一战略的核心是 Accum®，Defence Therapeutics 的专有精确药物递送平台，旨在解决肿瘤学中最持久的挑战之一：有效的细胞内递送。通过增强细胞摄取和药物释放，Accum®在较低剂量下提高治疗效力，有潜力减少毒性并改善患者对先进癌症治疗的获取。</p>
<p>Defence 正在通过一种双重战略优先考虑这一平台和合作模式，该战略结合了内部研发项目与生物技术和制药生态系统中的战略合作伙伴关系。这种方法使得现有资产和下一代资产的增强成为可能，包括抗体药物偶联物（ADCs）、放射药物和其他复杂生物制剂，将传统上用于后期治疗的疗法转变为更安全、更有效的一线治疗选择。</p>
<p>“我们的重点很明确：解决细胞层面的药物递送，以便无论是由 Defence 开发还是由我们的合作伙伴开发的癌症疗法，都能发挥其全部潜力，” Defence Therapeutics 首席执行官 Sébastien Plouffe 表示。“Accum®旨在为合作伙伴创造最佳价值，同时最终为患者提供更好的治疗结果。”</p>
<p>通过这一精炼的定位，Defence Therapeutics 重申了其对精准肿瘤学、合作和将前沿科学转化为改变生命的治疗的承诺，其商业模式旨在为合作伙伴创造可扩展的价值，并为股东创造长期价值。要了解更多信息或探索合作机会，请访问 <strong>www.defencetherapeutics.com</strong> 或联系 <strong>info@defencetherapeutics.com</strong>。</p>
<p><strong>关于 Defence Therapeutics：</strong></p>
<p>Defence Therapeutics 是一家上市生物技术公司，致力于使癌症治疗更有效和更安全。通过其 Accum®精确药物递送平台，Defence 正在努力提高抗体药物偶联物（ADCs）和其他复杂生物制剂在较低剂量下的效力，目标是减少副作用并改善对先进疗法的获取。通过追求前沿科学，并与制药和生物技术合作伙伴合作，Defence 努力为最需要的患者带来变革性疗法。要了解更多关于 Defence Therapeutics 的信息并探索合作机会，请访问 www.defencetherapeutics.com 或联系 info@defencetherapeutics.com。</p>
<p>如需更多信息：</p>
<p>Sébastien Plouffe</p>
<p>首席执行官、创始人及董事</p>
<p>电话：（514）947-2272</p>
<p>Splouffe@defencetherapeutics.com</p>
<p>www.defencetherapeutics.com</p>
<p><strong>关于 “前瞻性” 信息的警示声明</strong></p>
<p>本发布包含某些可能被视为 “前瞻性声明” 的内容。除历史事实外，本发布中的所有声明，涉及公司预期发生的事件或发展，均为前瞻性声明。前瞻性声明是指非历史事实的声明，通常但不总是通过 “预期”、“计划”、“预计”、“相信”、“打算”、“估计”、“项目”、“潜在” 等词语或 “将”、“会”、“可能”、“能够” 或 “应该” 发生的事件或条件来识别。尽管公司相信这些前瞻性声明中表达的预期基于合理假设，但这些声明并不保证未来的表现，实际结果可能与前瞻性声明中的结果有实质性差异。可能导致实际结果与前瞻性声明中的结果有实质性差异的因素包括监管行动、市场价格、资本和融资的持续可用性，以及一般经济、市场或商业条件。投资者被警告，任何此类声明并不保证未来的表现，实际结果或发展可能与前瞻性声明中预测的结果有实质性差异。前瞻性声明基于公司管理层在声明发布时的信念、估计和意见。除非适用证券法要求，否则公司不承担在管理层的信念、估计或意见或其他因素发生变化时更新这些前瞻性声明的义务。</p>
<p>CSE 及其市场监管机构（根据 CSE 政策中的定义）对本发布的充分性或准确性不承担责任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/280931_8f462d43e4ade8b1_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/280931_8f462d43e4ade8b1_logo.jpg"/></p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/280931</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/280931/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/280931/375"/></p>

<p>Defence Therapeutics Inc. 宣布战略转型，专注于其 Accum® 精准药物递送平台，旨在提高癌症生物制剂的有效性。该公司计划通过内部开发和战略合作推进这一平台，目标是提高治疗效力并降低毒性。首席执行官 Sébastien Plouffe 强调了优化药物递送以最大化患者治疗效果的目标。这一精细化战略突显了 Defence 对精准肿瘤学的承诺，以及在生物科技生态系统内的合作，旨在为患者提供变革性的治疗</p>

<p>Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (&#34;Defence&#34; or the &#34;Company&#34;), a publicly traded biotechnology company, today announced an evolution of its corporate positioning to reflect its focus as a precision intracellular drug-delivery company advancing its proprietary Accum® platform through both internal development programs and strategic partnerships. Designed to unlock the full potential of complex cancer biologics, Accum® enhances intracellular delivery to increase therapeutic potency while reducing toxicity.</p>
<div class="lb-trans"><p>蒙特利尔，魁北克 --（Newsfile Corp. -2026 年 1 月 21 日）- Defence Therapeutics Inc.（CSE: DTC）（FSE: DTC）（OTCQB: DTCFF）（“Defence” 或 “公司”），一家上市生物技术公司，今天宣布其企业定位的演变，以反映其作为一家精确细胞内药物递送公司的专注，正在通过内部开发项目和战略合作伙伴关系推进其专有的 Accum®平台。Accum®旨在释放复杂癌症生物制剂的全部潜力，增强细胞内递送以提高治疗效力，同时降低毒性。</p>
</div><p>At the center of this strategy is Accum®, Defence Therapeutics' proprietary precision drug-delivery platform designed to solve one of oncology's most persistent challenges: effective intracellular delivery. By enhancing cellular uptake and payload release, Accum® increases therapeutic potency at lower doses, with the potential to reduce toxicity and improve patient access to advanced cancer treatments.</p>
<div class="lb-trans"><p>这一战略的核心是 Accum®，Defence Therapeutics 的专有精确药物递送平台，旨在解决肿瘤学中最持久的挑战之一：有效的细胞内递送。通过增强细胞摄取和药物释放，Accum®在较低剂量下提高治疗效力，有潜力减少毒性并改善患者对先进癌症治疗的获取。</p>
</div><p>Defence is prioritizing this platform and partnering model through a dual strategy that combines internal R&amp;D programs with strategic partnerships across the biotech and pharmaceutical ecosystem. This approach enables the enhancement of both existing and next-generation assets, including antibody-drug conjugates (ADCs), radiopharmaceuticals, and other complex biologics, transforming therapies traditionally used in later lines into safer, more effective first-line treatment options.</p>
<div class="lb-trans"><p>Defence 正在通过一种双重战略优先考虑这一平台和合作模式，该战略结合了内部研发项目与生物技术和制药生态系统中的战略合作伙伴关系。这种方法使得现有资产和下一代资产的增强成为可能，包括抗体药物偶联物（ADCs）、放射药物和其他复杂生物制剂，将传统上用于后期治疗的疗法转变为更安全、更有效的一线治疗选择。</p>
</div><p>&#34;Our focus is clear: solve drug delivery at the cellular level so cancer therapies, whether developed by Defence or by our partners, can reach their full potential,&#34; said Sébastien Plouffe, CEO of Defence Therapeutics. &#34;Accum® is designed to create optimal value for partners while ultimately delivering better outcomes for patients.&#34;</p>
<div class="lb-trans"><p>“我们的重点很明确：解决细胞层面的药物递送，以便无论是由 Defence 开发还是由我们的合作伙伴开发的癌症疗法，都能发挥其全部潜力，” Defence Therapeutics 首席执行官 Sébastien Plouffe 表示。“Accum®旨在为合作伙伴创造最佳价值，同时最终为患者提供更好的治疗结果。”</p>
</div><p>With this refined positioning, Defence Therapeutics reinforces its commitment to precision oncology, collaboration, and translating cutting-edge science into life-changing treatments, with a business model designed to generate scalable value for partners and long-term value for shareholders. To learn more or explore partnering opportunities, please visit <strong>www.defencetherapeutics.com</strong> or contact <strong>info@defencetherapeutics.com</strong>.</p>
<div class="lb-trans"><p>通过这一精炼的定位，Defence Therapeutics 重申了其对精准肿瘤学、合作和将前沿科学转化为改变生命的治疗的承诺，其商业模式旨在为合作伙伴创造可扩展的价值，并为股东创造长期价值。要了解更多信息或探索合作机会，请访问 <strong>www.defencetherapeutics.com</strong> 或联系 <strong>info@defencetherapeutics.com</strong>。</p>
</div><p><strong>About Defence Therapeutics:</strong></p>
<div class="lb-trans"><p><strong>关于 Defence Therapeutics：</strong></p>
</div><p>Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.</p>
<div class="lb-trans"><p>Defence Therapeutics 是一家上市生物技术公司，致力于使癌症治疗更有效和更安全。通过其 Accum®精确药物递送平台，Defence 正在努力提高抗体药物偶联物（ADCs）和其他复杂生物制剂在较低剂量下的效力，目标是减少副作用并改善对先进疗法的获取。通过追求前沿科学，并与制药和生物技术合作伙伴合作，Defence 努力为最需要的患者带来变革性疗法。要了解更多关于 Defence Therapeutics 的信息并探索合作机会，请访问 www.defencetherapeutics.com 或联系 info@defencetherapeutics.com。</p>
</div><p>For further information:</p>
<div class="lb-trans"><p>如需更多信息：</p>
</div><p>Sebastien Plouffe</p>
<div class="lb-trans"><p>Sébastien Plouffe</p>
</div><p>CEO, Founder and Director</p>
<div class="lb-trans"><p>首席执行官、创始人及董事</p>
</div><p>P: (514) 947-2272</p>
<div class="lb-trans"><p>电话：（514）947-2272</p>
</div><p>Splouffe@defencetherapeutics.com</p>
<div class="lb-trans"><p>Splouffe@defencetherapeutics.com</p>
</div><p>www.defencetherapeutics.com</p>
<div class="lb-trans"><p>www.defencetherapeutics.com</p>
</div><p><strong>Cautionary Statement Regarding &#34;Forward-Looking&#34; Information</strong></p>
<div class="lb-trans"><p><strong>关于 “前瞻性” 信息的警示声明</strong></p>
</div><p>This release includes certain statements that may be deemed &#34;forward-looking statements&#34;. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words &#34;expects&#34;, &#34;plans&#34;, &#34;anticipates&#34;, &#34;believes&#34;, &#34;intends&#34;, &#34;estimates&#34;, &#34;projects&#34;, &#34;potential&#34; and similar expressions, or that events or conditions &#34;will&#34;, &#34;would&#34;, &#34;may&#34;, &#34;could&#34; or &#34;should&#34; occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.</p>
<div class="lb-trans"><p>本发布包含某些可能被视为 “前瞻性声明” 的内容。除历史事实外，本发布中的所有声明，涉及公司预期发生的事件或发展，均为前瞻性声明。前瞻性声明是指非历史事实的声明，通常但不总是通过 “预期”、“计划”、“预计”、“相信”、“打算”、“估计”、“项目”、“潜在” 等词语或 “将”、“会”、“可能”、“能够” 或 “应该” 发生的事件或条件来识别。尽管公司相信这些前瞻性声明中表达的预期基于合理假设，但这些声明并不保证未来的表现，实际结果可能与前瞻性声明中的结果有实质性差异。可能导致实际结果与前瞻性声明中的结果有实质性差异的因素包括监管行动、市场价格、资本和融资的持续可用性，以及一般经济、市场或商业条件。投资者被警告，任何此类声明并不保证未来的表现，实际结果或发展可能与前瞻性声明中预测的结果有实质性差异。前瞻性声明基于公司管理层在声明发布时的信念、估计和意见。除非适用证券法要求，否则公司不承担在管理层的信念、估计或意见或其他因素发生变化时更新这些前瞻性声明的义务。</p>
</div><p>Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.</p>
<div class="lb-trans"><p>CSE 及其市场监管机构（根据 CSE 政策中的定义）对本发布的充分性或准确性不承担责任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/280931_8f462d43e4ade8b1_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/8000/280931_8f462d43e4ade8b1_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280931</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/280931</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/280931/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/280931/375"/></p>

Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics | DTCFF Stock News

StockTitan

医疗业 ETF - Vanguard

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

ESC NEUBASE THERAPEUTI

Black Diamond Therapeutics

美国制药 ETF - iShares

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

Turn Therapeutics

Defence Therapeutics 聚焦于精准药物递送，旨在充分发挥癌症生物制剂的潜力 | DTCFF 股票新闻